Open-label, Single-arm, Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Phase of Trial: Phase IV
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Amgen
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 28 Feb 2019 Planned End Date changed from 11 Mar 2019 to 20 May 2019.
- 28 Feb 2019 Planned primary completion date changed from 11 Mar 2019 to 20 May 2019.